^
CANCER:

Adrenal Cortex Carcinoma

No biomarker
Adrenal Cortex Carcinoma
mitotane
Sensitive: A1 - Approval
No biomarker
Adrenal Cortex Carcinoma
cisplatin + carboplatin + etoposide IV + mitotane + SGN-15
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
cisplatin
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
cisplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
carboplatin + etoposide IV + mitotane
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
carboplatin + doxorubicin hydrochloride + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
carboplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
cisplatin + etoposide IV + mitotane
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
cisplatin + doxorubicin hydrochloride + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
streptozocin
Sensitive: A2 - Guideline
No biomarker
Adrenal Cortex Carcinoma
mitotane + streptozocin
Sensitive: A2 - Guideline
MSI-H/dMMR
Adrenal Cortex Carcinoma
pembrolizumab
Sensitive: C1 - Off-label
RRM1 underexpression
Adrenal Cortex Carcinoma
mitotane
Sensitive: C3 – Early Trials
TMB-L
Adrenal Cortex Carcinoma
mitotane
Sensitive: C3 – Early Trials
MSH2 mutation
Adrenal Cortex Carcinoma
pembrolizumab
Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion
Adrenal Cortex Carcinoma
erdafitinib
Sensitive: C4 – Case Studies
TOP2A overexpression
Adrenal Cortex Carcinoma
rubitecan
Sensitive: D – Preclinical
TOP2A overexpression
Adrenal Cortex Carcinoma
teniposide
Sensitive: D – Preclinical
CDK1 overexpression
Adrenal Cortex Carcinoma
carfilzomib + DSP-2033
Sensitive: D – Preclinical
CDK4 overexpression
Adrenal Cortex Carcinoma
palbociclib
Sensitive: D – Preclinical
TOP2A overexpression
Adrenal Cortex Carcinoma
etoposide oral
Sensitive: D – Preclinical
TOP2A overexpression
Adrenal Cortex Carcinoma
pirarubicin
Sensitive: D – Preclinical
TOP2A overexpression
Adrenal Cortex Carcinoma
mitoxantrone
Sensitive: D – Preclinical
AURKA overexpression
Adrenal Cortex Carcinoma
SA033 + AMG 900
Sensitive: D – Preclinical
AURKB overexpression
Adrenal Cortex Carcinoma
SA033 + AMG 900
Sensitive: D – Preclinical
TOP2A overexpression
Adrenal Cortex Carcinoma
idarubicin hydrochloride
Sensitive: D – Preclinical
TOP2A overexpression
Adrenal Cortex Carcinoma
SA033
Sensitive: D – Preclinical
TOP2A overexpression
Adrenal Cortex Carcinoma
daunorubicin
Sensitive: D – Preclinical
TOP2A overexpression
Adrenal Cortex Carcinoma
aclarubicin
Sensitive: D – Preclinical
AURKB overexpression
Adrenal Cortex Carcinoma
mitotane + AMG 900
Sensitive: D – Preclinical
AURKA overexpression
Adrenal Cortex Carcinoma
mitotane + AMG 900
Sensitive: D – Preclinical
AURKA overexpression
Adrenal Cortex Carcinoma
AMG 900
Sensitive: D – Preclinical
AURKB overexpression
Adrenal Cortex Carcinoma
AMG 900
Sensitive: D – Preclinical
MET overexpression
Adrenal Cortex Carcinoma
cabozantinib capsule
Sensitive: D – Preclinical
CDK2 overexpression
Adrenal Cortex Carcinoma
carfilzomib + DSP-2033
Sensitive: D – Preclinical
EZH2 overexpression
Adrenal Cortex Carcinoma
mitotane + EZH2 inhibitor
Sensitive: D – Preclinical
ASXL1 overexpression
Adrenal Cortex Carcinoma
EDP
Resistant: D – Preclinical